🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists hope that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The study enrolled hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to make available and distribute the drug in many regions with limited resources.

Clinicians directly involved have expressed optimism. Having a single-dose, oral treatment like this is described as a "game-changer" for public health efforts. This is considered essential to alleviate the strain of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.